The landscape of COVID-19 is changing. The UK government seems to have decided that it is time for COVID-19 to be an endemic virus and have dropped all restrictions and it is now a free for all.
Cases of COVID-19 are on the up but luckily deaths are not matching, this due to vaccination and the nature of the COVID-19 variant in play at the moment (Omicron). So at some time it is likely that COVID-19 is coming your way. Remember the nature of symptoms are changing although we seem to be fixated on fever loss of smell and cough, omicron is associated with a runny nose, headache, fatigue, sneezing (if you have been vaccinated) sore throat (according to the ZOE app).
However, if you do get one of these
You may get an option of an anti-viral. What is on offer is changing all the time and depends on the prevailing variant of SARS-CoV-2. Alpha gave way to delta, which has given way to omicron and BA.1 varinat is giving way to omincron BA.2. As omicron became more prevalent bamlanivimab/etesivimab casiririvimab/imdevimab and regdavimab has become less useful. Sotrovimab is seen as the option against omicron (BA.1) but it is not good if you are infected with BA.2. Tixagevimab is no good against omicron
Seroneutralization of Omicron BA.1 and BA.2 in patients receiving anti-SARS-CoV-2 monoclonal antibodies. Bruel, T., Hadjadj, J., Maes, P., Planas, D., Seve, A., Staropoli, I., Guivel-Benhassine, F., Porrot, F., Bolland, W.-H., Nguyen, Y., Casadevall, M., Charre, C., Pere, H., Veyer, D., Prot, M., Baidaliuk, A., Cuypers, L., Planchais, C., Mouquet, H., Baele, G., Mouthon, L., Hocqueloux, L., Simon-Loriere, E., Andre, E., Terrier, B., Prazuck, T., Schwartz, O.10.1101/2022.03.09.22272066
The SARS-CoV-2 Omicron BA.1 variant has been supplanted in many countries by the BA.2 sub-lineage. BA.2 differs from BA.1 by about 21 mutations in its spike. Human anti-spike monoclonalantibodies(mAbs)areusedforpreventionortreatmentofCOVID-19. However, the capacity of therapeutic mAbs to neutralize BA.1 and BA.2 remains poorly characterized. Here, we first compared the sensitivity of BA.1 and BA.2 to neutralization by 9 therapeutic mAbs. In contrast to BA.1, BA.2 was sensitive to Cilgavimab, partly inhibited by Imdevimab and resistant to Adintrevimab and Sotrovimab. Two combinations of mAbs, Ronapreve (Casirivimab + Imdevimab) and Evusheld (Cilgavimab + Tixagevimab), are indicated as a pre-exposure prophylaxis in immunocompromised persons at risk of severe disease. We analyzed sera from 29 such individuals, up to one month after administration of Ronapreve and/or Evusheld. After treatment, all individuals displayed elevated antibody levels in their sera and neutralized Delta with high titers. Ronapreve recipients did not neutralize BA.1 and weakly impaired BA.2. With Evusheld, neutralization of BA.1 and BA.2 was detected in 19 and 29 out of 29 patients, respectively. As compared to Delta, titers were more severely decreased against BA.1 (344-fold) than BA.2 (9-fold). We further report 4 breakthrough Omicron infections among the 29 participants. Therefore, BA.1 and BA.2 exhibit noticeable differences in their sensitivity to therapeutic mAbs. Anti-Omicron activity of Ronapreve, and to a lesser extent that of Evusheld, is reduced in patients sera, a phenomenon associated with decreased clinical efficacy.